Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SUPN
Supernus Pharmaceuticals, Inc.
stock NASDAQ

At Close
Jul 17, 2026 3:59:59 PM EDT
48.04USD-0.342%(-0.17)439,397
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 17, 2026 9:29:30 AM EDT
48.31USD+0.207%(+0.10)4,399
After-hours
Jul 17, 2026 4:00:30 PM EDT
48.04USD-0.010%(0.00)84,997
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 8, 2021
08:49AM EST  Supernus Resubmits NDA For SPN-830 Apomorphine Infusion Device For Treatment Of Motor Fluctuations In PD   RTTNews
08:33AM EST  Supernus Pharma Reports Resubmission Of New Drug Application For SPN-830 Apomorphine Infusion Device   Benzinga
08:30AM EST  Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device   GlobeNewswire Inc
Nov 24, 2021
06:59PM EST  The attack had no significant impact on the business and did not cause any significant disruption to Companys operations   GlobeNewswire Inc
09:13AM EST  Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).   GlobeNewswire Inc
Nov 23, 2021
08:00AM EST  Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.   GlobeNewswire Inc
Nov 18, 2021
08:00AM EST  Supernus to Participate in Annual Piper Sandler Healthcare Conference   GlobeNewswire Inc
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
Nov 3, 2021
05:33PM EDT  Supernus Pharmaceuticals: Q3 Earnings Insights   Benzinga
04:40PM EDT  Supernus Pharmaceuticals Q3 EPS $0.40 Beats $0.23 Estimate   Benzinga
09:19AM EDT  The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
Nov 2, 2021
06:30PM EDT  LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS   PR Newswire
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 20, 2021
08:00AM EDT  -- Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversity -- Nearly one-in-ten or 6.1 million children and adolescents are affected by ADHD   GlobeNewswire Inc
Oct 11, 2021
03:17PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher   Benzinga
12:13PM EDT  Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals   Benzinga
06:54AM EDT  Supernus Pharmaceuticals Inc. (SUPN) agreed to acquire Adamas Pharmaceuticals Inc. (ADMS) for total consideration up to $9.10 per share. The acquisition is expected to be significantly accretive in 2022.   RTTNews
06:36AM EDT  Supernus To Acquire Adamas Through Tender Offer For $8.10/Shr Cash   RTTNews
06:32AM EDT  Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals For $8.10/Share Or An Aggregate Of ~$400M   Benzinga
06:30AM EDT  Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals   GlobeNewswire Inc
Sep 2, 2021
06:45PM EDT  Supernus Announces Qelbree sNDA for Adult   GlobeNewswire Inc
09:00AM EDT  Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Companys management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences.   GlobeNewswire Inc
Aug 20, 2021
02:35PM EDT  Return on Capital Employed Insights for Supernus Pharmaceuticals   Benzinga
Aug 16, 2021
01:26PM EDT  Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization   Benzinga
Aug 4, 2021
05:03PM EDT  Supernus Pharmaceuticals Sees FY21 Sales $550M-$580M Vs. $558.02M Est.   Benzinga
05:02PM EDT  Supernus Pharmaceuticals Q2 EPS $0.43 Beats $0.20 Estimate, Sales $141.30M Beat $134.87M Estimate   Benzinga
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Jul 19, 2021
04:40PM EDT  Supernus Pharmaceuticals Says On Jul. 13 Entered API Supply Agreement With Bachem Americas; Financial Terms Not Disclosed   Benzinga
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
May 26, 2021
04:42PM EDT  Supernus Pharmaceuticals Says On May 20 Entered Into Commercial Supply Agreement With Catalent Pharma Solutions With Effective Date Of May 12, 2021   Benzinga
May 25, 2021
08:30AM EDT  Supernus to Present at Jefferies Virtual Healthcare Conference   GlobeNewswire Inc
May 24, 2021
08:39AM EDT  Supernus Pharmaceuticals Announces Availability Of Qelbree   Benzinga
08:30AM EDT  Qelbree (viloxazine extended-release capsules),   GlobeNewswire Inc
May 19, 2021
04:16PM EDT  Supernus Pharmaceuticals Says Co. And Newron Received Notice Letters From MSN Laboratories, Optimus Pharma And Zenara Pharma Advising Supernus Of Filings Of Abbreviated NDAs To FDA Seeking Approval Of Mesylate Tablets   Benzinga
May 5, 2021
04:14PM EDT  Supernus Pharmaceuticals Sees FY21 Sales $550M-$580M Vs. $569.54M Est.   Benzinga
04:13PM EDT  Supernus Pharmaceuticals Q1 EPS $0.11 Misses $0.24 Estimate, Sales $130.90M Beat $129.20M Estimate   Benzinga
04:01PM EDT  Supernus Announces First Quarter 2021 Financial Results   GlobeNewswire Inc
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 13, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021   Benzinga
08:07AM EDT  Jefferies Upgrades Supernus Pharmaceuticals to Buy, Raises Price Target to $40   Benzinga
Apr 5, 2021
09:55AM EDT  Shares of Supernus Pharmaceuticals, Inc. (SUPN) are up more than 7% Monday morning at $28.72.   RTTNews
07:44AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Apr. 5, 2021: STZ, IINN, LEVI, SUPN, PSMT   Benzinga
06:07AM EDT  Supernus Shares Rise 9% in the Premarket After Company Announced on Friday FDA Approval of Qelbree for the Treatment of ADHD   Benzinga
Apr 2, 2021
10:12PM EDT  Supernus Pharmaceuticals Inc. (SUPN) said that the U.S. Food and Drug Administration approved Qelbree or viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder or ADHD in pediatric patients 6 to 17 years of age.   RTTNews
04:58PM EDT  Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade   GlobeNewswire Inc
Feb 26, 2021
09:00AM EST  Supernus to Present at Cowen Healthcare Conference   GlobeNewswire Inc
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 25, 2021
04:37PM EST  Supernus Pharmaceuticals: Q4 Earnings Insights   Benzinga
04:01PM EST  Supernus Pharmaceuticals Sees FY21 Sales $550M-$580M vs. $581.47M Est.   Benzinga
04:01PM EST  Supernus Pharmaceuticals Q4 EPS $0.57 Beats $0.52 Estimate, Sales $143.56M Miss $146.19M Estimate   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 23, 2021
09:00AM EST  Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the fourth quarter and full year 2020 after the market closes on Thursday, February 25, 2021.   GlobeNewswire Inc
Feb 22, 2021
08:07AM EST  UPDATE: Supernus Says New PDUFA Target Action Date Set For Early Apr. 2021   Benzinga
08:07AM EST  Supernus Pharma Reports Received Notice From FDA Co.'s New Drug Application Resubmission For SPN-812 For Treatment Of ADHD Is Considered Class I Resubmission, Assigns 2-Month Timeline For Review   Benzinga
08:00AM EST  Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date   GlobeNewswire Inc
Feb 8, 2021
09:01AM EST  Supernus Says Resubmits New Drug Application For SPN-812 For Treatment Of ADHD In Pediatric Patients   Benzinga
09:00AM EST  Supernus Resubmits New Drug Application for SPN-812 for the   GlobeNewswire Inc
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 27, 2021
10:07AM EST  Stocks That Hit 52-Week Highs On Wednesday   Benzinga
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
Jan 26, 2021
08:07AM EST  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 6, 2021
05:29PM EST  Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference   GlobeNewswire Inc
Dec 23, 2020
10:31AM EST  Shares of Supernus Pharmaceuticals, Inc. (SUPN) are currently gaining nearly 14%. The company on Tuesday after the bell revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD.   RTTNews
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
06:09AM EST  A Peek Into The Markets: US Stock Futures Up Ahead Of Economic Reports   Benzinga
12:48AM EST  Why Supernus Shares Rallied 24% After-Hours On Tuesday   Benzinga
Dec 22, 2020
06:07PM EST  Supernus Announces Positive Results from Phase III Study for   GlobeNewswire Inc
Dec 7, 2020
09:49AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
Nov 28, 2020
01:08PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Nov 26, 2020
12:30AM EST  Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (Supernus or the Company) (NASDAQ:SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Nov 18, 2020
10:00PM EST  Supernus to Participate in Annual Piper Sandler Healthcare Conference   GlobeNewswire Inc
Nov 11, 2020
11:14PM EST  Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the following virtual investor conferences in November 2020.   GlobeNewswire Inc
09:45PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 9, 2020
09:30AM EST  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
11:36AM EST  Why Supernus Pharmaceuticals Stock Is Trading Higher Today   Benzinga
10:24AM EST  Mid-Morning Market Update: Markets Open Higher; Performance Food Earnings Top Views   Benzinga
10:14AM EST  Shares of drug maker Supernus Pharmaceuticals, Inc. (SUPN) are rising more than 22% Wednesday morning on upbeat third quarter results. The company has also raised its full-year product sales outlook.   RTTNews
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
05:56AM EST  What's moving these stocks in the pre-market hours today?   RTTNews
Nov 3, 2020
04:34PM EST  Supernus Pharmaceuticals Raises FY20 Sales Guidance From $460M-$500M To $500M-$525M Vs. $486.54M Est   Benzinga
04:32PM EST  Supernus Pharmaceuticals Q3 EPS $0.74 Beats $0.30 Estimate, Sales $155.10M Beat $130.66M Estimate   Benzinga
04:30PM EST  Supernus Announces Third Quarter 2020 Financial Results   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
04:07AM EST  Earnings Scheduled For November 3, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 5, 2020
04:00PM EDT  Supernus Pharmaceuticals Appoints James Kelly as Chief Financial   GlobeNewswire Inc
04:00PM EDT  Supernus Pharma Names James Kelly CFO   Benzinga
Sep 28, 2020
10:01AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Sep 14, 2020
08:27AM EDT  Supernus Submits NDA To FDA For Its Apomorphine Infusion Pump SPN-830   RTTNews
08:17AM EDT  Supernus Submits NDA For SPN-830 For Continuous Treatment Of ON-OFF Episodes In Adults With Parkinson's Disease Who Have Failed Two Treatments   Benzinga
08:15AM EDT  Supernus Submits NDA for SPN-830 for Continuous Treatment of   GlobeNewswire Inc
Sep 9, 2020
04:30PM EDT  Supernus to Present at the Morgan Stanley 18th Annual Global   GlobeNewswire Inc
Sep 2, 2020
04:30PM EDT  Supernus to Present at the Wells Fargo Virtual Health Care Conference   GlobeNewswire Inc
Aug 18, 2020
06:06PM EDT  Supernus Announces Second Quarter 2020 Financial Results   GlobeNewswire Inc
04:02AM EDT  Earnings Scheduled For August 18, 2020   Benzinga
Aug 11, 2020
04:41PM EDT  Supernus Announces Q2 Prelim. Sales Of $126.7M   Benzinga
04:30PM EDT  Supernus Announces Preliminary Second Quarter 2020 Revenue   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC